Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
In a previous phase II study, the safety and efficacy of a novel formulation of malathion
0.5% was evaluated in patients 2 years of age and older. Based on the results of that study,
this formulation is currently in a phase III study for that population.
The current study will use blood markers and clinical evaluations to determine the safety and
tolerability of this formulation when used in children 6-24 months of age.